This article is more than 5 years old. Information may no longer be current.
PCV13 safe, immunogenic in previously vaccinated HIV patients
Click Here to Manage Email Alerts
Recently published data suggest the 13-valent pneumococcal conjugate vaccine triggered anticapsular immunoglobulin G and opsonophagocytic antibody responses in HIV-infected adults who were previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine.
Researchers conducted a phase 3, open-label, single-arm study to evaluate the safety and immunogenicity of three doses of the 13-valent pneumococcal conjugate vaccine (PCV13) given at 6-month intervals in adults with HIV who previously had been vaccinated with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at one or two doses. All patients had CD4 cell counts of at least 200 cells/mm3.
Of the 331 enrolled patients, 329 received at least a single dose of PCV13, 300 were vaccinated with two doses, and 279 underwent vaccination with all three doses.
The researchers found increases in anticapsular polysaccharide IgG levels and opsonophagocytic antibody titers at 1 month after administration of all three doses of PCV13. Similar antibody levels were seen after each dose, and responses were comparable regardless of whether the patients previously had received one or two doses of PPSV23. The most common adverse event was pain at the injection site, and systemic adverse events were infrequent.
The findings are consistent with other studies of the 7-valent pneumococcal conjugate vaccine (PCV7) in adults with HIV that demonstrated a functional antibody response after vaccination, according to the researchers.
“Based on the potential benefit, several countries recommend a dose of PCV13 for HIV-infected adults, including those previously vaccinated with PPSV23,” they wrote. “A significant number of HIV-infected adults have already received PPSV23, and the findings of safety and immunogenicity from the current study support the use of PCV13 in this population.”
Disclosure: See the study for a full list of relevant financial disclosures.
Click Here to Manage Email Alerts